Business Description
SCYNEXIS Inc
NAICS : 325412
SIC : 2834
ISIN : US8112922005
Total Employee Number:
29Description
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 28.75 | |||||
Equity-to-Asset | 0.53 | |||||
Debt-to-Equity | 0.05 | |||||
Debt-to-EBITDA | -0.08 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -6.76 | |||||
Beneish M-Score | 1.57 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 51.1 | |||||
3-Year EBITDA Growth Rate | 51.1 | |||||
3-Year EPS without NRI Growth Rate | 47.6 | |||||
3-Year FCF Growth Rate | 61.6 | |||||
3-Year Book Growth Rate | 125.5 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 36.06 | |||||
9-Day RSI | 31.06 | |||||
14-Day RSI | 30.72 | |||||
3-1 Month Momentum % | -18.69 | |||||
6-1 Month Momentum % | 15.99 | |||||
12-1 Month Momentum % | -7.54 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.94 | |||||
Quick Ratio | 3.94 | |||||
Cash Ratio | 3.73 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -10 | |||||
Shareholder Yield % | 27.02 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -119.86 | |||||
Net Margin % | -120.51 | |||||
EBITDA Margin % | -120.51 | |||||
FCF Margin % | -29.09 | |||||
OCF Margin % | -29.09 | |||||
ROE % | -55.19 | |||||
ROA % | -38.75 | |||||
ROIC % | -164.67 | |||||
3-Year ROIIC % | 1694.53 | |||||
ROC (Joel Greenblatt) % | -1327.4 | |||||
ROCE % | -46.01 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 4 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 6.71 | |||||
PS Ratio | 1.2 | |||||
PB Ratio | 0.72 | |||||
Price-to-Tangible-Book | 0.72 | |||||
EV-to-EBIT | 0.77 | |||||
EV-to-EBITDA | 0.77 | |||||
EV-to-Revenue | -0.93 | |||||
EV-to-Forward-Revenue | 23.19 | |||||
EV-to-FCF | 3.21 | |||||
Price-to-GF-Value | 0.17 | |||||
| Price-to-Net-Current-Asset-Value | 1.13 | |||||
| Price-to-Net-Cash | 1.3 | |||||
Earnings Yield (Greenblatt) % | 129.87 | |||||
FCF Yield % | -15.49 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SCYX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
SCYNEXIS Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 20.344 | ||
| EPS (TTM) ($) | -3.84 | ||
| Beta | -0.0012 | ||
| 3-Year Sharpe Ratio | -0.47 | ||
| 3-Year Sortino Ratio | -0.65 | ||
| Volatility % | 52.86 | ||
| 14-Day RSI | 30.72 | ||
| 14-Day ATR ($) | 0.352188 | ||
| 20-Day SMA ($) | 4.34694 | ||
| 12-1 Month Momentum % | -7.54 | ||
| 52-Week Range ($) | 3.68 - 10.48 | ||
| Shares Outstanding (Mil) | 9.93 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
SCYNEXIS Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
SCYNEXIS Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 129 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 45 days | ||
| General meeting for 2026 | 2026-06-25 09:30 | 3.87 (+2.11%) | ||
| 0.125:1 Stock Split | 2026-06-01 | 5.64 (-4.73%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 7.33 (-4.38%) | ||
| Annual report for 2025 | 2026-03-04 | 6.01 (-0.67%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-04 | 6.01 (-0.67%) | ||
| Third quarter earnings results for 2025 | 2025-11-05 | 5.04 (-3.06%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 6.88 (-3.38%) | ||
| General meeting for 2025 | 2025-06-25 09:30 | 5.93 (+0.42%) |
Show
Entries
SCYNEXIS Inc Frequently Asked Questions
What is SCYNEXIS Inc(SCYX)'s stock price today?
The current price of SCYX is $3.85. The 52 week high of SCYX is $10.48 and 52 week low is $3.68.
When is next earnings date of SCYNEXIS Inc(SCYX)?
The next earnings date of SCYNEXIS Inc(SCYX) is 2026-08-13 Est..
Does SCYNEXIS Inc(SCYX) pay dividends? If so, how much?
SCYNEXIS Inc(SCYX) does not pay dividend.
Guru Commentaries on NAS:SCYX
No articles.
Press Release
Articles on SCYNEXIS Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers